Boehringer Ingelheim
勃林格殷格翰
Boehringer Ingelheim is the world's largest private pharmaceutical company, founded in 1885 and focused on human biopharmaceuticals, chemical products, and animal health . In China, its drug development department has partnered with Triastek, a Yunqi Capital portfolio company, to apply 3D printing technology to rapid formulation R&D for new drug molecules—a collaboration that began with Triastek's selection into Boehringer Ingelheim's global opnMe program in 2021 and advanced to a formal agreement by March 2023 .
AI-generated — may contain errors, please verify.
Coverage
Over $1.2 Billion in Total Value: Triastek Announces First-Ever Technology Platform International Collaboration in Chinese Pharmaceutical History with BioNTech | Yunqi Capital
Empowering Digital Transformation in Pharmaceutical Development
云启资本·"Triastek" Closes 150 Million Yuan Pre-C Round to Accelerate Commercialization of 3D-Printed Drugs | Yunqi Capital
Pioneering a New Era of Intelligent Drug Discovery
云启资本·How Can a "3D Printer" Boost Productivity in the Pharmaceutical Industry? | The B-Side of Entrepreneurship
Take the hard, meaningful path
云启资本·"Triastek" Partners with World's Largest Private Pharmaceutical Company: 3D Printing Technology Accelerates New Drug R&D | Yunqi Tech π
Triastek Enters Partnership with Boehringer Ingelheim
云启资本·
